Abstracts Archive - Page 1782 of 2425 - ACR Meeting Abstracts

Abstract Number: 1393 • 2015 ACR/ARHP Annual Meeting
Diagnostic Categorization of Ocular Sarcoidosis Based on the International Criteria Proposed By the First International Workshop on Ocular Sarcoidosis. a Case Series of 11 Spanish Patients
Carlos Francisco Meneses Villalba¹, Olga Maiz Alonso¹, Ana Blanco², César Antonio Egües Dubuc¹, Miren Uriarte Ecenarro¹, Nerea Errazquin Aguirre¹, Jesus A. Valero¹ and Joaquin Maria Belzunegui Otano¹, ¹Rheumatology, Donostia University Hospital, Donostia, Spain, ²Ophthalmology, Donostia University Hospital, Donostia, Spain
Background/Purpose: Sarcoidosis is a multisystemic disorder of unknown cause. About 30-60% of patients have ocular involvement consistent in bilateral uveitis. Recently, the clasification criteria proposed by…
Abstract Number: 1394 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics of Sarcoid Arthropathy: A Population-Based Study
Patompong Ungprasert¹, Cynthia S. Crowson² and Eric L. Matteson³, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: The epidemiology and clinical characteristics of sarcoid arthropathy are not well-described as only referral-based studies have been reported. This study aimed to use the…
Abstract Number: 1395 • 2015 ACR/ARHP Annual Meeting
Prevalence and Significance of MEFV GENE Mutations in Patients with Sarcoidosis
Senol Kobak¹, Fidan Sever², Ozlem Goksel³, Tuncay Goksel³, Mehmet Orman⁴ and Afig Berdeli⁵, ¹Rheumatology, Sifa University Faculty of Medicine, 35100, Turkey, ²Chest Disease, Sifa University, Izmir, Turkey, ³Chest Disease, Ege University, Izmir, Turkey, ⁴Ege University Department of Statistic, Associated Professor, Izmir, Turkey, ⁵Genetics and Molecular Medicine, Ege University, Izmir, Turkey
Background/Purpose: Sarcoidosis is a chronic granulomatous disease. Pyrin, is encoded by the MEFV gene and has anti-inflammatory effects in the inflammasoma regulation. MEFV gene mutations…
Abstract Number: 1396 • 2015 ACR/ARHP Annual Meeting
Long Term Outcome of Neurosarcoidosis
Catherine Chapelon¹, Bastien Joubert¹, Lucie Biard², David Saadoun³, Mathieu Resche Regon⁴, Fanny Domont¹, Lea Savey¹, Didier Dormont¹ and Patrice Cacoub⁵, ¹Hôpital Pitié Salpétrière, AP-HP, UPMC, Univ Paris 06, Paris, France, ²Biostatistics, Saint-Louis Hospital, Paris, France, ³Department of Internal Medicine and clinical Immunology. French National Reference Center for Autoimmune Diseases. DHU I2B (Inflammation, Immunotherapy and Biotherapy), UPMC, Paris VI, Hôpital Pitié Salpétrière, AP-HP, UPMC, Univ Paris 06, Paris, France, ⁴biostatistics Saint Louis Hospital, paris, France, ⁵Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France
Background/Purpose: Although clinical and imaging features of neurosarcoidois (NS) have been described, few studies have reported on the long-term outcome. We report the long-term outcome…
Abstract Number: 1397 • 2015 ACR/ARHP Annual Meeting
Successful Treatment of Cardiac Sarcoidosis with Biologic and Immunosuppressive Combination Therapy
Maya Estephan¹, Mehrdad Maz², Mark Hamblin³ and Julian Magadan¹, ¹Division of Allergy, Clinical Immunology, and Rheumatology, University of Kansas Medical Center, Kansas City, KS, ²Division of Rheumatology, University of Kansas Medical Center, Kansas City, KS, ³Pulmonary and Critical Care Medicine, ILD Clinic, University of Kansas Medical Center, Kansas city, KS
Background/Purpose: Although cardiac involvement is symptomatic in only 5% of patients with sarcoidosis, it is considered an important prognostic factor and the second leading cause…
Abstract Number: 1398 • 2015 ACR/ARHP Annual Meeting
Musculoskeletal and Serologic Findings in an Adult Cystic Fibrosis Clinic Population-a Systematic Review and Collation with Disease Status
Mohamed Elarabi^1,2, Katherine Griffin³, Luxme Mahendira^1,4, Jenna Sykes³, Erin Norris^1,2, Anne Stephenson^1,3, Elizabeth Tullis^1,3 and Laurence Rubin^1,5, ¹University of Toronto, Toronto, ON, Canada, ²Rheumatology, Saint Michael’s Hospital, Toronto, ON, Canada, ³Respirology, Saint Michael’s Hospital, Toronto, ON, Canada, ⁴30 Bond Street, Saint Michael’s Hospital, Toronto, ON, Canada, ⁵Saint Michael’s Hospital, Toronto, ON, Canada
Background/Purpose: Cystic fibrosis (CF) is a genetic disorder characterized by exocrine gland production of highly viscous mucus, leading to obstructive and inflammatory changes in the…
Abstract Number: 1399 • 2015 ACR/ARHP Annual Meeting
Patterns of Arthropathy in Patients with Cystic Fibrosis
Amanda Schnell¹, Muhammad Imran², Michael Crosser³ and Mehrdad Maz⁴, ¹Internal Medicine, University of Kansas Medical Center, Kansas City, KS, ²Rheumatology, University of Kansas Medical Center, Kansas City, KS, ³Pulmonary and Critical Care, University of Kansas Medical Center, Kansas City, KS, ⁴Division of Rheumatology, University of Kansas Medical Center, Kansas City, KS
Background/Purpose: There are limited published studies about patterns of arthropathy seen in cystic fibrosis (CF) patients. The objective of this study was to determine the…
Abstract Number: 1400 • 2015 ACR/ARHP Annual Meeting
Hyperferritinemia and Fever in Adults
Kensuke Nakanishi and Mitsuyo Kinjo, Rheumatology, Okinawa Chubu Hospital, Uruma, Japan
Background/Purpose: Clinical associations of hyperferritinemia include: hepatocellular injury, hemophagocytic lymphohistiocytosis (HLH), hematologic malignancy, adult-onset Still’s disease (AOSD), and iron overload. Fever of undetermined origin (FUO)…
Abstract Number: 1401 • 2015 ACR/ARHP Annual Meeting
Is There Any Difference Between Autoimmune or Hemato-Oncology Etiology of Macrophage Activation Syndrome?
César Antonio Egües Dubuc, Miren Uriarte Ecenarro, Nerea Errazquin Aguirre, Olga Maiz Alonso, Iñaki Hernando Rubio and Joaquin Maria Belzunegui Otano, Rheumatology, Donostia University Hospital, Donostia, Spain
Background/Purpose: Macrophage activation syndrome (MAS) is a group of diseases, especially autoimmune (AI) and hemato-oncology (HO). So it will be interesting to find any clinical…
Abstract Number: 1402 • 2015 ACR/ARHP Annual Meeting
Development of Systemic Juvenile Idiopathic Arthritis Manifestations Following Remission of Hemophagocytic Lymphohistiocytosis
Baruch Goldberg¹, Eyal Muscal², Marietta De Guzman³ and Carl Allen⁴, ¹Pediatric Rheumatology, Texas Children's Hospital, Houston, TX, ²Pediatric Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Pediatric Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Pediatric Hematology and Oncology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal pathologic inflammatory process resulting from impaired immune function due to inherited gene mutations or secondary to…
Abstract Number: 1403 • 2015 ACR/ARHP Annual Meeting
Immune Related Adverse Events Associated with Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review of Case Reports
Noha Abdel-Wahab^1,2 and Maria E. Suarez-Almazor³, ¹Rheumatology & Rehabilitation Department, Assiut University Hospital, Egypt, Assiut, Egypt, ²The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, USA, Houston, TX, ³General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Background: The recent discovery of the immune checkpoint blockade that targets the regulatory pathways in T cells to enhance antitumor immune responses has led…
Abstract Number: 1404 • 2015 ACR/ARHP Annual Meeting
Death and Infection Rates Appear Reduced in a Modern Cohort of ICU Patients with Rheumatic Disease
Erin M. Wilfong¹, Sara G. Murray², Gabriela Schmajuk³ and Jinoos Yazdany⁴, ¹Division of Rheumatology, Department of Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, ⁴University of California, San Francisco, San Francisco, CA
Background/Purpose: Prior studies of patients with rheumatic diseases admitted to ICU care have been limited to case series; none included patients admitted after 2010. We…
Abstract Number: 1405 • 2015 ACR/ARHP Annual Meeting
Tocilizumab Serum Levels and Antidrug Antibodies and Its Relationship with Disease Activity in Rheumatic Diseases
Samantha Rodriguez-Muguruza¹, Melania Martínez-Morillo¹, Juana Sanint², Bibiana Quirant Sr.³, Aina Teniente Sr.⁴, Agueda Prior⁵, Anne Riveros-Frutos⁶, Susana Holgado⁷, Maria Lourdes Mateo⁷, Alejandro Olivé⁸, Jeronima Cañellas⁵ and Xavier Tena⁷, ¹Rheumatology, Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ²Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ³Immunology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁴immunology, Hospital Universitari Germans Trias i Pujol, barcelona, Spain, ⁵Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁶Microbiology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁷Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ⁸Hospital Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Tocilizumab (TCZ) is a humanized anti-IL-6 receptor-blocking monoclonal antibody used for the treatment of rheumatoid arthritis (RA), idiopathic juvenile arthritis (IJA) and off-label in…
Abstract Number: 1406 • 2015 ACR/ARHP Annual Meeting
The Treatment of Undifferentiated Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Voké Kakpovbia¹, Maria A. Lopez-Olivo², Jude Des Bordes³, Robin Christensen⁴ and Maria E. Suarez-Almazor², ¹Baylor College of Medicine, Houston, TX, ²General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark
Background/Purpose: While various studies have looked at possible RA therapies for undifferentiated arthritis (UA), there remains no consensus on optimal management strategies. We undertook a…
Abstract Number: 1407 • 2015 ACR/ARHP Annual Meeting
New Clinical Features of Pyogenic Arthritis, Pyoderma Gangrenosum, and Acne Syndrome
Patrycja Hoffmann¹, Amanda K. Ombrello², Deborah Stone³, Anne Jones⁴, Karyl Barron⁵ and Daniel Kastner⁶, ¹Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, MD, ²Inflammatory Diseases Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³NIH/NHGRI, Bethesda, MD, ⁴NHGRI/NIH, Bethesda, MD, ⁵National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ⁶Metabolic, Cardiovascular, and Inflammatory Disease Genomics Branch, NIH/NHGRI, Bethesda, MD
Background/Purpose: The dominantly inherited pyogenic arthritis pyoderma gangrenosum and acne (PAPA) syndrome is caused by mutations in PSTPIP1. It is one of the least understood…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].